The collapse of Purdue Pharma and the Sackler dynasty

A lesson on distorted incentives and hidden risk

My professional insights · Lyudmil Karaulanov · 6 min read

Published: 16 October 2026 · Version 1.1

An organisation’s real priorities are revealed not by its official declarations on ethics, but by the behaviour it actually rewards with cash bonuses, commissions and career advancement. When the reward system encourages only short-term aggressive turnover, without taking account of hidden legal, medical and reputational risk, closing deals at any cost ceases to be an accident and becomes a designed organisational choice. The historical case of the American pharmaceutical company Purdue Pharma and its owners, the Sackler family, provides one of the most dramatic lessons in the destructive power of distorted incentives. This case is an opportunity to apply the concepts analysed in the piece “You get what you reward: the architecture of incentives and hidden risk” in the section Ownership and control.

OxyContin came onto the market in 1996. Growing its sales became a central goal for Purdue. But the problem cannot be proven merely by the claim that all bonuses were tied entirely to prescriptions. The stronger factual basis is the established violations in marketing and control, including the conduct admitted by the company in 2020. [1]

Purdue pleaded guilty to three federal charges, including fraudulent conduct towards the American authorities and schemes to improperly incentivise prescribing. The company also admitted that it had presented its programme against the diversion of drugs as effective despite its substantial shortcomings. The problem is therefore not a proven absence of absolutely all rules, but a grave failure of their operation and of management accountability. [1]

The human cost comes first: addiction, lives lost and lasting consequences for families and communities. The opioid crisis has many participants and causes; it cannot be attributed to one company alone. This does not diminish the responsibility for Purdue’s specifically admitted conduct. Separately from the corporate admission, certain members of the Sackler family entered into a civil settlement in 2020; it is not equivalent to a personal criminal conviction. [1]

Purdue entered bankruptcy proceedings in 2019. In 2024 the U.S. Supreme Court rejected the release, provided for in the plan at the time, of persons outside the bankruptcy from claims without the consent of the affected creditors. After a new plan, on 1 May 2026 the shutdown of Purdue was announced and Knoa Pharma, owned by a non-profit foundation, began operating. The family has no stake in the new company. This is a specific change of ownership and control, not proof that the family’s entire personal wealth has disappeared. [2-3]

The analytical lesson for the owner remains unsparing: you get what you reward if control cannot stop harmful behaviour. The bonus scheme alone does not explain the whole case. It works together with management’s decisions, the quality of supervision and the way warning signals are handled. When the financial result justifies ignoring them, the risk is shifted onto people outside the organisation, and later onto its capital.

A practical architecture requires the result to be measured after its quality has been taken into account. A sale that creates unacceptable harm or a violation should not earn the same recognition as sustainable revenue. Part of remuneration can depend on a subsequent review, and serious violations can lead to the loss or recovery of a bonus under the applicable rules.

An independent path for bad news is also needed. The control function must be able to reach the board without permission from the executive whose results it reviews. The owners should see not only turnover, but also the grounds for terminated deals, recurring complaints and unresolved signals. Control without the right of escalation easily becomes documentation of decisions already taken.

The counterpoint is not the removal of incentives for growth. Excessively complex indicators can dissipate responsibility just as successfully as the single indicator of “turnover”. The aim is an understandable model with clear limits, under which neither the founder nor the heir can informally lift the restrictions in the name of short-term results.

Where is the point of instability?

What this concept means →

The point of instability arises when a complete architectural gap opens between declared corporate principles and the real system of remuneration. When bonuses and recognition are tied solely to the visible quantitative result, with no brakes for quality, legal risk and safety, employees orient themselves towards pursuing the bonus at any cost, shifting irreversible systemic risk onto the organisation itself.

This material is of a general analytical nature and does not constitute individual legal, tax, financial or investment advice.